Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts
- Biognosys opens a new CRO facility in Massachusetts to provide high-throughput proteome profiling services for US biopharma customers.
- The facility will focus on TrueDiscovery® data-independent acquisition (DIA) discovery proteomics services, powered by the Bruker timsTOF mass spectrometry platform.
- The expansion aims to bring cutting-edge proteomics closer to US customers, enabling them to leverage the potential of proteomics for therapeutic discoveries and drug development.
- None.
Insights
The establishment of Biognosys' new proteomics facility in Massachusetts is a strategic move that positions the company to better serve the US biopharmaceutical market. By localizing services, Biognosys is likely to enhance its competitive edge by offering reduced turnaround times and improved logistical efficiency for its US-based clients. This proximity to the biotech hub in the Boston-Cambridge area could foster stronger partnerships and collaborations, potentially leading to increased service demand and revenue growth.
The focus on TrueDiscovery® data-independent acquisition services highlights a commitment to high-throughput and cost-efficient proteomics, which is essential for drug discovery and development. The use of the Bruker timsTOF mass spectrometry platform underscores the importance of advanced technology in providing high-quality services. The facility's future expansion into additional proteomics services indicates a forward-thinking approach and a potential growth trajectory for the company's service offerings.
Biognosys' operational expansion into the US is a reflection of the growing importance of proteomics in drug discovery. The company's dual-lab strategy, with a continued commitment to innovation at its Swiss headquarters and expansion of its service portfolio in the US, is poised to meet the increasing demand for specialized proteomics services. This strategic positioning not only caters to immediate market needs but also serves as a long-term investment in the burgeoning field of personalized medicine and biomarker discovery.
The emphasis on industry-leading depth and reproducibility in proteome profiling can be seen as an alignment with the industry's shift towards precision medicine, where detailed proteomic data is crucial. The impact of this expansion may be observed in the potential acceleration of therapeutic discovery and development timelines, which is of significant interest to stakeholders across the biopharma industry.
For investors, the opening of a new CRO facility by Biognosys in Massachusetts may signal a period of growth and an opportunity for the company to capture a larger market share within the US. The investment in cutting-edge mass spectrometry technology and the proprietary TrueDiscovery® platform could translate into a competitive advantage and drive customer retention and acquisition. However, the capital expenditure associated with this expansion and the ongoing operational costs will need to be balanced against the expected increase in revenue.
While the immediate financial impact may not be evident, the long-term return on investment will depend on the company's ability to effectively leverage its proximity to key US markets and integrate its services into the drug development pipelines of its clients. The market will be observing how this expansion affects Biognosys' market position relative to its competitors and whether it can translate its technological edge into sustainable financial performance.
-
The new CRO facility for proteomics services in
Newton, Massachusetts ensures closer proximity to US customers -
Biognosys’ center of excellence for proteomics innovation at its headquarters near
Zurich, Switzerland continues to offer its entire portfolio of services for discovery, targeted, and structural proteomics for all regions, including theAmericas
ZURICH &
Biognosys
The
“The opening of our new CRO facility in
Dr. Rohan Thakur, President Life Sciences Mass Spectrometry at Bruker, said: “Offering 4D-Proteomics CRO services from the inventors of Spectronaut – the leading DIA proteomics software, now augmented with deep learning – will provide broader access to proteomics in key research areas such as chemoproteomics, immunopeptidomics, or plasma proteomics. Proteomics at the depth and scale of Biognosys’ TrueDiscovery platform will accelerate insights into the complexity of disease biology and is another step forward in the post-genomic era of drug discovery and development.”
In the last 15 years, Biognosys has served US biopharma companies from its facility near
Biognosys’ laboratory at its headquarters in
- TrueDiscovery® services for unbiased discovery proteomics from biofluids, tissues and cells, with applications ranging from biomarker discovery to mechanism of action studies, phosphorylation profiling, and immunopeptidome profiling
- TrueSignature® custom targeted proteomics panels for pharmacodynamic and clinical biomarker monitoring through absolute protein quantification in clinical trials
- TrueTarget® services for novel drug target identification and validation powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys
“Our dual-lab strategy underscores our dedication to providing leading-edge, accessible proteomics solutions,” said Biognosys’ Chief Officer of Scientific Operations (COSO), Dr. Jakob Vowinckel. “The synergy between our Swiss and US facilities allows us to serve diverse customer needs, fostering innovation and collaborations.”
To offer customers industry-leading solutions for a wide range of biological applications, Biognosys remains committed to employing mass spectrometry instruments from multiple vendors in their research services.
About TrueDiscovery®
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM™) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in compliance with GCP guidelines. For more information, visit truediscovery.bio.
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123705269/en/
Media
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 44 244 50 07
yves.serroen@biognosys.com
Source: Bruker Corporation
FAQ
What is the focus of Biognosys' new CRO facility in Massachusetts?
What is the goal of the expansion of Biognosys in the US?
Where is the headquarters of Biognosys located?
